

Corporate Profile

Meridian is a fully integrated life science company that develops, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company's shares are traded through NASDAQ's Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

Primary IR Contact

Melissa Lueke
Executive Vice President
Chief Financial Officer
Meridian Bioscience, Inc.

Stock Performance

VIVO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$14.20
Change (%)	▲ 0.15 (1.07%)
Volume	182,144
52 Week Low	\$10.75
Market Cap	\$592,952,389
Rolling EPS	0.50
PE Ratio	28.021
Shares Outstanding	42,203,017

Data as of 09/22/17 4:00 p.m. ET



Recent Press Releases

9/19/2017

Meridian Contributes to Upcoming "LEADCON 2017" – Third Annual International Conference on the Prevention of Lead and Heavy Metal Toxicity in Hyderabad, India

9/5/2017

Meridian Launches TRU Block® ULTRA – A Powerful Immunoassay Interference Blocker

8/9/2017

Meridian Initiates Clinical Trials for New Neonatal Saliva CMV illumigene Test

8/8/2017

Meridian Bioscience Introduces the Expansion of Its ImmunoCard STAT!® Product Line

8/8/2017

Meridian Bioscience Elects John Rice to the Board of Directors


Upcoming Events

There are currently no events scheduled.

Recent SEC Filings

Filing Date	Form	Description
08/25/17	4	Statement of changes in beneficial ownership of securities
08/09/17	4	Statement of changes in beneficial ownership of securities
08/09/17	3	Initial filing by director officer or owner of more than ten percent.
08/09/17	10-Q	Quarterly report which provides a continuing view of a company's financial position

Analyst Estimates / Ratings



Management

John A. Kraeutler

Chairman of the Board, Chief Executive Officer

Lawrence J. Baldini

Executive Vice President and President, Global Operations

Marco Calzavara

President, Meridian Bioscience Europe

Richard L. Eberly

Executive Vice President, President and Chief Commercial Officer

Slava A. Elagin

Executive Vice President, Research and Product Development

Melissa A. Lueke

Executive Vice President, Chief Financial Officer

Susan D. Rolih

Executive Vice President Regulatory Affairs and Quality Assurance

Lourdes G. Weltzien

Vice President & General Manager, President Asia Pacific Markets

Amy M. Winslow

Executive Vice President, President and CEO Magellan Diagnostics

EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Sep 17	0.14	0.14	0.15
QTR	Dec 17	0.16	0.16	0.16
QTR	Mar 18	0.21	0.21	0.21
QTR	Jun 18	0.17	0.17	0.18
FY	Sep 17	0.67	0.67	0.68
FY	Sep 18	0.68	0.68	0.70

Board of Directors

John A. Kraeutler

Chairman of the Board, Chief Executive Officer

James M. Anderson

Retired President and Chief Executive Officer Cincinnati Children's Hospital Medical Center

David C. Phillips

Co-founder Cincinnati Works, Inc

Dwight (Dee) E. Ellingwood

President, D.E.E. Strategy Consulting, LLC

John C. McIlwraith

Co-founder Allos Ventures

Catherine A. Sazdanoff

Chief Business Officer of Strata Oncology, Inc

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	253	624.73	93.5	39,468,586
Mutual Fund	291	293.44	48.8	20,587,850
Insider *	14	15.56	2.4	1,028,169

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Brown Capital Management, LLC	5,650,457	13.4	-32,638	06/30/17
BlackRock Institutional Trust Company, N.A.	4,785,974	11.3	5,775	06/30/17
The Vanguard Group, Inc.	4,018,985	9.5	334,480	06/30/17
Renaissance Technologies LLC	1,967,300	4.7	-20,976	06/30/17
Dimensional Fund Advisors, L.P.	1,667,971	4.0	240,143	06/30/17
State Street Global Advisors (US)	1,231,092	2.9	-12,755	06/30/17
Norges Bank Investment Management (NBIM)	1,136,022	2.7	0	12/31/16
New York State Common Retirement Fund	1,059,987	2.5	-1	06/30/17
M & G Investment Management Ltd.	923,400	2.2	-251,100	06/30/17
Boston Trust & Investment Management Company	709,363	1.7	-226,227	06/30/17

Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Minimum 20 minutes delayed